Patent intelligence · CA
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
Patent details — CA 3263063
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Mar 28, 2024
- Expiration
- Mar 23, 2044
- Applicant
- ALFASIGMA SPA [IT]
- CPC classes
- A61K 31/ 4709 A I, A61K/314709, A61K/90053, A61P/100
Quick answer
CA 3263063 (VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Mar 28, 2024. Expires Mar 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALFASIGMA SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4709 A I, A61K/314709, A61K/90053, A61P/100, A61P/104, A61P/2502
More from ALFASIGMA SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026027669
BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
IT 202300012522
FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.
granted -
AU 2023257308
USES OF FARNESOID X RECEPTOR AGONISTS
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
IT 202300001434
PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.
granted -
IT 202200013882
PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.
granted
Frequently asked questions
What is US patent 3263063?
CA 3263063 (VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Mar 28, 2024. Expires Mar 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3263063?
ALFASIGMA SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3263063 expire?
Our index shows an expiration date of Mar 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.